1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Canada >
  5. Quebec >
  6. XenoTherapeutics Acquires Repare Therapeutics

M&A Deal Summary

XenoTherapeutics Acquires Repare Therapeutics

On November 14, 2025, XenoTherapeutics acquired life science company Repare Therapeutics

Acquisition Highlights
  • This is XenoTherapeutics’ 2nd transaction in the Life Science sector.
  • This is XenoTherapeutics’ 2nd transaction in Canada.
  • This is XenoTherapeutics’ 1st transaction in Quebec.

M&A Deal Summary
Date 2025-11-14
Target Repare Therapeutics
Sector Life Science
Buyer(s) XenoTherapeutics
Deal Type Add-on Acquisition
Advisor(s) Leerink Partners (Financial)
Cooley (Legal)

Target

Repare Therapeutics

Montreal, Quebec, Canada
Repare Therapeutics is a precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Polθ inhibitor programs. Repare Therapeutics was founded in 2016 and is headquartered in Montreal, Quebec.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

XenoTherapeutics

Boston, Massachusetts, United States
Category Company
Founded 1996
Sector Life Science
Employees316
Revenue 9M USD (2022)
DESCRIPTION

XenoTherapeutics is a 501(c)(3) research foundation focused on advancing xenotransplantation through scientific research, clinical development, and public education. XenoTherapeutics is based in Boston, Massachusetts.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
State: Quebec M&A 1 of 1
Country: Canada M&A 2 of 2
Year: 2025 M&A 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2025-07-14 ESSA

Vancouver, British Columbia, Canada

ESSA is a pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer ("CRPC") in patients whose disease is progressing despite treatment with current therapies. ESSA's proprietary "aniten" compounds bind to the N-terminal domain of the androgen receptor ("AR"), inhibiting AR-driven transcription and the AR signaling pathway in a unique manner which bypasses the drug resistance mechanisms associated with current anti-androgens. ESSA was founded in 2009 and is based in Vancouver, Canada.

Buy -
Mergr

Solution for

Product

Company

Legal